Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker TAK
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Giles Richard Platford President, International Business Unit | TAK Takeda Pharmaceutical Company Limited | 55,617 | $1.1M | — | Nov 1, 2026 | Form 4 ↗ 6 days later · 55,617 shares | Form 144 ↗ |
| Oct 30, 2026 | Teresa Bitetti President, Global Oncology Business Unit | TAK Takeda Pharmaceutical Company Limited | 46,609 | $940.1K | — | Nov 1, 2026 | Form 4 ↗ 5 days later · 46,609 shares | Form 144 ↗ |
| Sep 10, 2026 | Lauren Rusckowski Duprey Chief Transformation Officer | TAK Takeda Pharmaceutical Company Limited | 34,535 | $634.4K | — | Sep 10, 2026 | Form 4 ↗ 5 days later · 34,535 shares | Form 144 ↗ |
| Sep 2, 2026 | Plump Andrew Stewart Officer | TAK Takeda Pharmaceutical Company Limited | 116,191 | $2.1M | 10b5-1 | Sep 2, 2026 | Form 4 ↗ 1 day later · 116,191 shares | Form 144 ↗ |
| Aug 19, 2026 | Plump Andrew Stewart Officer | TAK Takeda Pharmaceutical Company Limited | 19,651 | $363.3K | 10b5-1 | Aug 19, 2026 | Form 4 ↗ 2 days later · 19,651 shares | Form 144 ↗ |
| Aug 14, 2026 | Nicola Greenway Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | 12,980 | $225.7K | — | Aug 14, 2026 | Form 4 ↗ 5 days later · 12,980 shares | Form 144 ↗ |
| Aug 10, 2026 | Elaine Shannon President, Global Supply & Quality | TAK Takeda Pharmaceutical Company Limited | 20,363 | $355.3K | — | Aug 11, 2026 | Form 4 ↗ 2 days later · 3,978 shares | Form 144 ↗ |
| Aug 6, 2026 | Nicola Greenway Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | 34,603 | $578.6K | — | Aug 7, 2026 | Form 4 ↗ 6 days later · 34,603 shares | Form 144 ↗ |
| Jul 13, 2026 | Marcello Pignagnoli Agosti Interim Head, Strategy and Portfolio De… | TAK Takeda Pharmaceutical Company Limited | 24,887 | $416.9K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 22,957 shares | Form 144 ↗ |
| Jul 13, 2026 | Lauren Rusckowski Duprey Chief Transformation Officer | TAK Takeda Pharmaceutical Company Limited | 51,579 | $863.9K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 47,586 shares | Form 144 ↗ |
| Jul 13, 2026 | Giles Platford President, International Business Unit | TAK Takeda Pharmaceutical Company Limited | 33,696 | $564.4K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 31,083 shares | Form 144 ↗ |
| Jul 13, 2026 | Natalie Furney Global General Counsel | TAK Takeda Pharmaceutical Company Limited | 33,454 | $560.4K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 30,868 shares | Form 144 ↗ |
| Jul 13, 2026 | Gabriele Ricci Chief Data & Technology Officer | TAK Takeda Pharmaceutical Company Limited | 27,197 | $455.5K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 25,088 shares | Form 144 ↗ |
| Jul 13, 2026 | Nicola Greenway Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | 7,348 | $123.1K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 34,603 shares | Form 144 ↗ |
| Jul 13, 2026 | Elaine Shannon President, Global Supply & Quality | TAK Takeda Pharmaceutical Company Limited | 4,319 | $72.4K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 3,978 shares | Form 144 ↗ |
| Jul 13, 2026 | Ramy Riad President, Plasma-Derived Therapies Bus… | TAK Takeda Pharmaceutical Company Limited | 7,889 | $132.1K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 7,277 shares | Form 144 ↗ |
| Jul 13, 2026 | Awny Farajallah Chief Medical Officer | TAK Takeda Pharmaceutical Company Limited | 15,188 | $254.4K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 14,006 shares | Form 144 ↗ |
| Jul 13, 2026 | Rhonda Pacheco President, US Business Unit and US Coun… | TAK Takeda Pharmaceutical Company Limited | 18,316 | $306.8K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 16,901 shares | Form 144 ↗ |
| Jul 13, 2026 | Andrew Plump President, Research & Development | TAK Takeda Pharmaceutical Company Limited | 179,239 | $3.0M | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 165,393 shares | Form 144 ↗ |
| Jul 13, 2026 | Teresa Bitetti President, Global Oncology Business Unit | TAK Takeda Pharmaceutical Company Limited | 54,210 | $908.0K | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 50,012 shares | Form 144 ↗ |
| Jul 13, 2026 | Julie Kim President and CEO | TAK Takeda Pharmaceutical Company Limited | 96,558 | $1.6M | — | Jul 13, 2026 | Form 4 ↗ 30 days later · 89,090 shares | Form 144 ↗ |
| Dec 9, 2025 | Lauren Rusckowski Duprey Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | 29,619 | $421.2K | — | Dec 9, 2025 | — | Form 144 ↗ |
| Dec 5, 2025 | Teresa Marie Bitetti President, Global Oncology Business Unit | TAK Takeda Pharmaceutical Company Limited | 87,023 | $1.2M | — | Dec 5, 2025 | — | Form 144 ↗ |
| Dec 4, 2025 | Giles Richard Platford President, Plasma-Derived Therapies Bus… | TAK Takeda Pharmaceutical Company Limited | 58,421 | $836.0K | — | Dec 4, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Christophe Pierre Weber Chief Executive Officer | TAK Takeda Pharmaceutical Company Limited | 34,857 | $537.5K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Akiko Amakawa Corporate Strategy Officer & CEO Chief… | TAK Takeda Pharmaceutical Company Limited | 5,608 | $86.5K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Elaine Mary Shannon Global Quality Officer | TAK Takeda Pharmaceutical Company Limited | 4,477 | $69.0K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Marcello Pignagnoli Agosti Global Business Development Officer | TAK Takeda Pharmaceutical Company Limited | 18,622 | $287.2K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Gabriele Ricci Chief Data & Technology Officer | TAK Takeda Pharmaceutical Company Limited | 26,874 | $414.4K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Lauren Rusckowski Duprey Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | 40,919 | $631.0K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Thomas Wozniewski Global Manufacturing & Supply Officer | TAK Takeda Pharmaceutical Company Limited | 6,136 | $94.6K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Julie Kim President, US Business Unit | TAK Takeda Pharmaceutical Company Limited | 58,559 | $903.0K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Andrew Plump President, Research & Development | TAK Takeda Pharmaceutical Company Limited | 169,313 | $2.6M | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Giles Richard Platford President, Plasma-Derived Therapies Bus… | TAK Takeda Pharmaceutical Company Limited | 28,552 | $440.3K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Teresa Marie Bitetti President, Global Oncology Business Unit | TAK Takeda Pharmaceutical Company Limited | 52,649 | $811.8K | — | Jul 9, 2025 | — | Form 144 ↗ |
| Jul 9, 2025 | Ramona A Sequeira President, Global Portfolio Division | TAK Takeda Pharmaceutical Company Limited | 102,972 | $1.6M | — | Jul 9, 2025 | — | Form 144 ↗ |
| Aug 22, 2024 | Giles Richard Platford President, Plasma-Derived Therapies Bus… | TAK Takeda Pharmaceutical Company Limited | 19,073 | $285.0K | — | Aug 23, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Thomas Wozniewski Global Manufacturing & Supply Officer | TAK Takeda Pharmaceutical Company Limited | 4,533 | $59.7K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Teresa Marie Bitetti President, Global Oncology Business Unit | TAK Takeda Pharmaceutical Company Limited | 38,479 | $507.2K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Ramona A Sequeira President, Global Portfolio Division | TAK Takeda Pharmaceutical Company Limited | 74,654 | $983.9K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Marcello Pignagnoli Agosti Global Business Development Officer | TAK Takeda Pharmaceutical Company Limited | 10,674 | $140.7K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Lauren Rusckowski Duprey Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | 27,603 | $363.8K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Julie Kim President, US Business Unit | TAK Takeda Pharmaceutical Company Limited | 37,219 | $490.5K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Giles Richard Platford President, Plasma-Derived Therapies Bus… | TAK Takeda Pharmaceutical Company Limited | 20,721 | $273.1K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Gabriele Ricci Chief Data & Technology Officer | TAK Takeda Pharmaceutical Company Limited | 6,132 | $80.8K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Elaine Mary Shannon Global Quality Officer | TAK Takeda Pharmaceutical Company Limited | 4,612 | $60.8K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Christophe Pierre Weber Chief Executive Officer | TAK Takeda Pharmaceutical Company Limited | 14,890 | $196.3K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Andrew Plump President, Research & Development | TAK Takeda Pharmaceutical Company Limited | 121,125 | $1.6M | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2024 | Akiko Amakawa Corporate Strategy Officer & CEO Chief… | TAK Takeda Pharmaceutical Company Limited | 6,048 | $79.7K | — | Jul 11, 2024 | — | Form 144 ↗ |
| Jul 10, 2023 | Thomas Wozniewski Global Manufacturing & Supply Officer | TAK Takeda Pharmaceutical Company Limited | 4,789 | $74.1K | — | Jul 11, 2023 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 7:38 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances